Systemic Immunosuppression for Prevention of Recurrent Tendon Adhesions.
Journal
Plastic and reconstructive surgery. Global open
ISSN: 2169-7574
Titre abrégé: Plast Reconstr Surg Glob Open
Pays: United States
ID NLM: 101622231
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
15
12
2020
accepted:
02
08
2021
entrez:
20
10
2021
pubmed:
21
10
2021
medline:
21
10
2021
Statut:
epublish
Résumé
The recovery for patients after tendon repair is frequently limited by development of tendon adhesions. This scar tissue formation is dependent on immune system activation. Tacrolimus has unique properties that may contribute to the prevention of overactive scarring by inhibition of inflammatory cytokines. Herein, we present a case using systemic immunosuppression to prevent recurrent adhesion accumulation in a patient with a prior spaghetti wrist injury. Tacrolimus began 1 week before repeat-secondary tenolysis surgery, and it continued for 3 months postoperative. Dosing was tapered to a serum level between 5 and 8 µg/L. The 27-year-old male patient suffered a volar wrist laceration transecting all flexor tendons and volar wrist nerves. He underwent immediate repair but had a poor outcome despite early range of motion therapy. A primary tenolysis only improved his average arc of finger motion from 72 to 95 degrees. Secondary tenolysis augmented with systemic tacrolimus improved his arc of finger motion from 95 to 202 degrees. Mechanistically, tacrolimus prevents proper function of activated T and B cells. This results in decreased proliferation, angiogenesis, and cytoskeletal organization of fibroblasts on inflammation and integrin adhesions, and it potentially explains the reduced tendon molecule adhesions seen in this patient. Tacrolimus may be effective in reducing motion, limiting tendon adhesions. The novel use of this medication resulted in the return of near-normal hand function in a patient placed on low-dose tacrolimus after primary tenolysis had failed.
Sections du résumé
BACKGROUND
BACKGROUND
The recovery for patients after tendon repair is frequently limited by development of tendon adhesions. This scar tissue formation is dependent on immune system activation. Tacrolimus has unique properties that may contribute to the prevention of overactive scarring by inhibition of inflammatory cytokines.
METHODS
METHODS
Herein, we present a case using systemic immunosuppression to prevent recurrent adhesion accumulation in a patient with a prior spaghetti wrist injury. Tacrolimus began 1 week before repeat-secondary tenolysis surgery, and it continued for 3 months postoperative. Dosing was tapered to a serum level between 5 and 8 µg/L.
RESULTS
RESULTS
The 27-year-old male patient suffered a volar wrist laceration transecting all flexor tendons and volar wrist nerves. He underwent immediate repair but had a poor outcome despite early range of motion therapy. A primary tenolysis only improved his average arc of finger motion from 72 to 95 degrees. Secondary tenolysis augmented with systemic tacrolimus improved his arc of finger motion from 95 to 202 degrees. Mechanistically, tacrolimus prevents proper function of activated T and B cells. This results in decreased proliferation, angiogenesis, and cytoskeletal organization of fibroblasts on inflammation and integrin adhesions, and it potentially explains the reduced tendon molecule adhesions seen in this patient.
CONCLUSIONS
CONCLUSIONS
Tacrolimus may be effective in reducing motion, limiting tendon adhesions. The novel use of this medication resulted in the return of near-normal hand function in a patient placed on low-dose tacrolimus after primary tenolysis had failed.
Identifiants
pubmed: 34667696
doi: 10.1097/GOX.0000000000003834
pmc: PMC8519255
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e3834Informations de copyright
Copyright © 2021 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The American Society of Plastic Surgeons.
Déclaration de conflit d'intérêts
Disclosure: The authors have no financial interest to declare in relation to the content of this article.
Références
Exp Biol Med (Maywood). 2017 Feb;242(4):384-396
pubmed: 27798123
Int Immunopharmacol. 2001 Jun;1(6):1219-26
pubmed: 11407316
J Int Oral Health. 2015 Mar;7(3):75-80
pubmed: 25878485
J Bone Joint Surg Am. 1962 Jan;44-A:49-64
pubmed: 14038468
J Hand Surg Am. 1977 Nov;2(6):462-70
pubmed: 925333
Ann Pharmacother. 1994 Apr;28(4):501-11
pubmed: 7518710
J Orthop Res. 2015 Jun;33(6):832-9
pubmed: 25641114
Int J Mol Med. 2018 May;41(5):2733-2743
pubmed: 29436608
J Bone Joint Surg Am. 2010 Jun;92(6):1381-9
pubmed: 20516313
J Hand Surg Am. 1982 Sep;7(5):436-44
pubmed: 7130650
Ther Drug Monit. 1995 Dec;17(6):584-91
pubmed: 8588225
Cell Motil Cytoskeleton. 1994;29(3):195-203
pubmed: 7895283
J Eur Acad Dermatol Venereol. 2014 Feb;28(2):204-15
pubmed: 23301526
Adv Wound Care (New Rochelle). 2018 Feb 1;7(2):29-45
pubmed: 29392092
J Hand Surg Am. 2010 Jun;35(6):1031-7; quiz 1038
pubmed: 20513584
Hand Clin. 2017 Aug;33(3):455-463
pubmed: 28673622
J Orthop Res. 2015 Jun;33(6):823-31
pubmed: 25676657
Br J Dermatol. 2012 Sep;167(3):532-41
pubmed: 22540338
J Bone Joint Surg Am. 1993 Jul;75(7):1004-14
pubmed: 8335659
J Hand Surg Am. 1977 Nov;2(6):441-51
pubmed: 336675
Adv Wound Care (New Rochelle). 2013 Jun;2(5):215-224
pubmed: 24527344
J Bone Joint Surg Am. 1991 Jul;73(6):868-81
pubmed: 1712787
Am J Pathol. 2009 Nov;175(5):1938-51
pubmed: 19834058
Int J Mol Sci. 2017 Jul 17;18(7):
pubmed: 28714933